Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
World Journal of Surgery|January 20, 2019
Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?Giovanni M Comacchio, Marco Schiavon, Danila Azzolina, et al.
Critical Reviews in Oncology/Hematology|August 16, 2024
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectivesAlessandra Ferro, Michele Bottosso, Maria Vittoria Dieci, et al.
Journal of Surgical Oncology|September 25, 2024
Safety and Efficacy of Salvage Surgery after Treatment With Immune-Checkpoint Adjuvant Inhibitors for Advanced Non-Small Cell Lung Cancer: A Multicentric StudyMarco Schiavon, Giorgio Cannone, Luca Bertolaccini, et al.
Cytokine|June 21, 2021
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratificationLoredana Urso, Micol Silic-Benussi, Alice Boscolo, et al.
Frontiers in Oncology|February 11, 2026
TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterationsThomas Newsom-Davis, Barbara Melosky, Rebecca S Heist, et al.
Thoracic Cancer|August 16, 2022
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancerAlessandra Buja, Giulia Pasello, Marco Schiavon, et al.
Cancer Letters|July 16, 2011
DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinomaEnrica Rumiato, Giulia Pasello, Marco Montagna, et al.
Frontiers in Oncology|July 18, 2022
Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-WorldGiulia Pasello, Martina Lorenzi, Giulia Pretelli, et al.
Cancers|August 28, 2025
Healthcare Costs by Comorbidity Patterns in Lung Cancer PatientsAlessandra Buja, Massimo Rugge, Marcello Di Pumpo, et al.
Cancers|May 14, 2025
Patterns of Comorbidities in Lung Cancer Patients and SurvivalAlessandra Buja, Marcello Di Pumpo, Massimo Rugge, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
World Journal of Surgery|January 20, 2019
Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?Giovanni M Comacchio, Marco Schiavon, Danila Azzolina, et al.
Critical Reviews in Oncology/Hematology|August 16, 2024
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectivesAlessandra Ferro, Michele Bottosso, Maria Vittoria Dieci, et al.
Journal of Surgical Oncology|September 25, 2024
Safety and Efficacy of Salvage Surgery after Treatment With Immune-Checkpoint Adjuvant Inhibitors for Advanced Non-Small Cell Lung Cancer: A Multicentric StudyMarco Schiavon, Giorgio Cannone, Luca Bertolaccini, et al.
Cytokine|June 21, 2021
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratificationLoredana Urso, Micol Silic-Benussi, Alice Boscolo, et al.
Frontiers in Oncology|February 11, 2026
TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterationsThomas Newsom-Davis, Barbara Melosky, Rebecca S Heist, et al.
Thoracic Cancer|August 16, 2022
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancerAlessandra Buja, Giulia Pasello, Marco Schiavon, et al.
Cancer Letters|July 16, 2011
DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinomaEnrica Rumiato, Giulia Pasello, Marco Montagna, et al.
Frontiers in Oncology|July 18, 2022
Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-WorldGiulia Pasello, Martina Lorenzi, Giulia Pretelli, et al.
Cancers|August 28, 2025
Healthcare Costs by Comorbidity Patterns in Lung Cancer PatientsAlessandra Buja, Massimo Rugge, Marcello Di Pumpo, et al.
Cancers|May 14, 2025
Patterns of Comorbidities in Lung Cancer Patients and SurvivalAlessandra Buja, Marcello Di Pumpo, Massimo Rugge, et al.
Pageof 17